Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November.

Two abstracts featuring SUPLEXA have been accepted for poster presentations, with one earning the prestigious ‘Top 100’ designation among 1,300 submissions. This recognition underscores the potential impact of our non-engineered, personalized cellular therapy in the fight against cancer.

Key Highlights:

1. Top 100 Abstract: “Transcriptional and proteomic insights into the immunomodulatory nature of SUPLEXA cells: An autologous cellular therapy for  cancers” (Abstract #378). Showcases SUPLEXA’s unique pharmacodynamic effects on patient peripheral blood composition.
2. Phase 1 Trial Results: “Final safety and efficacy update of SUPLEXA-101, a First-in-Human, Single Agent Study of SUPLEXA Therapeutic Cells in Metastatic Solid Tumors” (Abstract #608). Reports outcomes from our 35-patient study testing SUPLEXA in end-stage solid tumor patients.

SUPLEXA represents a paradigm shift in cancer immunotherapy, harnessing the power of patients’ own immune cells without the need for genetic engineering. Our Phase 1 trial has demonstrated an exceptional safety profile and encouraging efficacy signals across multiple tumor types.

We’re excited to share these groundbreaking results with the scientific community at SITC 2024. This recognition validates our innovative approach and brings us one step closer to potentially transforming cancer treatment.

If you will be attending SITC, we look forward to seeing you for our poster presentations at the Immune Engineering Workshop (Thursday Nov 7^th) and the Annual Meeting (Saturday November 9^th). Stay tuned for more updates as we prepare to advance SUPLEXA towards Phase 2 trials.